Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma
Open Access
- 3 August 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (1) , e17-e20
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemiaBlood, 2014
- Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotypingNature Biotechnology, 2014
- A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial CarcinomasNeoplasia, 2014
- AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemiaBlood, 2014
- Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy2012
- Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic LeukemiaCancer Cell, 2011
- A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphomaBlood, 2010
- Potential roles for the PIM1 kinase in human cancer – A molecular and therapeutic appraisalEuropean Journal of Cancer, 2008
- Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistanceCancer Cell, 2006
- Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumorsCell, 1989